Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 363

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 363
---
DTC”) model, we transitioned to a business -to-business-to-consumer(“B2B2C”) model. This strategic decision significantly impacted our operations, organizational structure, and go -to-marketstrategy. The transition was driven by the rising costs of logistics, customer acquisition, and digital marketing, which made the DTC model economically unsustainable for profitable scaling across Latin America. We initially invested heavily in market research, digital product development, user experience and user interface, and an e -commercechannel to validate consumer adoption. However, we concluded that scaling Rewell profitably through DTC across Latin America would require disproportionate investment with limited returns. The B2B2C model aligns with our broader strategy to scale through OmnigenicsAI’s laboratory consortium, including Heritas Diagnostics, and other local diagnostic laboratories. These partners, leveraging their market knowledge and trusted local relationships, are better positioned to distribute Rewell, manage customer relationships (including interpretation and coaching services where applicable), and oversee the commercialization of products such as the Continuous Evolution Kit. Under this model, we focus on test processing, platform operation, and results delivery, while partners lead distribution logistics and the customer relationships. During the DTC phase, we observed organic interest from wellness centers, healthcare professionals, and nutritionists seeking to resell Rewell, often choosing to manage the customer relationship independently rather than relying on our e -commerceplatform or internal genetic nutritionist services. This indicated organic market demand for a partner -baseddistribution model and a B2B2C distribution strategy. To support the shift to B2B2C, we streamlined operations by consolidating Rewell and Heritas Diagnostics under a unified structure and significantly downsized DTC -relatedfunctions, such as digital marketing, logistics, digital product design, and customer success management. As a result, our employee count was reduced from 49 as of June30, 2024, to 25 as of the date of this registration statement of which this prospectus is part, primarily impacting roles tied to the Rewell DTC operations. All Rewell products previously sold directly to consumers, including the Continuous Evolution Kit, will continue to be available through our network of B2B2C partners. These partners are responsible for the commercialization of the kits, the collection of samples, and, in many cases, the delivery of interpretation services. While the delivery mechanism has changed, the core service that offers the combination of genetic and microbiome testing with personalized health recommendations remains fundamentally the same. The transition away